Search: WFRF:(Richter Clark)
> (2020-2023) >
European LeukemiaNe...
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
-
- Hochhaus, A. (author)
- Universitätsklinikum Jena
-
- Baccarani, M. (author)
- University of Bologna,St. Orsola-Malpighi University Hospital
-
- Silver, R. T. (author)
- Cornell University
-
show more...
-
- Schiffer, C. (author)
- Karmanos Cancer Institute
-
- Apperley, J. F. (author)
- Imperial College London,Hammersmith Hospital
-
- Cervantes, F. (author)
- Institutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS)
-
- Clark, R. E. (author)
- University of Liverpool
-
- Cortes, J. E. (author)
- Medical College of Georgia
-
- Deininger, M. W. (author)
- Huntsman Cancer Institute
-
- Guilhot, F. (author)
- Poitiers University Hospital
-
- Hjorth-Hansen, H. (author)
- Norwegian University of Science and Technology
-
- Hughes, T. P. (author)
- South Australian Health and Medical Research Institute
-
- Janssen, J. J.W.M. (author)
- Academic Medical Center of University of Amsterdam (AMC)
-
- Kantarjian, H. M. (author)
- University of Texas
-
- Kim, D. W. (author)
- Catholic University of Korea,Seoul St. Mary's Hospital
-
- Larson, R. A. (author)
- University of Chicago
-
- Lipton, J. H. (author)
- University of Toronto
-
- Mahon, F. X. (author)
- University of Bordeaux
-
- Mayer, J. (author)
- University Hospital Brno,Masaryk University
-
- Nicolini, F. (author)
- Centre Léon Bérard
-
- Niederwieser, D. (author)
- University Hospital Leipzig
-
- Pane, F. (author)
- University of Naples Federico II
-
- Radich, J. P. (author)
- Fred Hutchinson Cancer Research Center
-
- Rea, D. (author)
- Saint-Louis Hospital, Paris
-
- Richter, J. (author)
- Lund University,Lunds universitet,Avdelningen för molekylärmedicin och genterapi,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Molecular Medicine and Gene Therapy,Department of Laboratory Medicine,Faculty of Medicine
-
- Rosti, G. (author)
- St. Orsola-Malpighi University Hospital,University of Bologna
-
- Rousselot, P. (author)
- Versailles Saint-Quentin-en-Yvelines University
-
- Saglio, G. (author)
- University of Turin
-
- Saußele, S. (author)
- Heidelberg University
-
- Soverini, S. (author)
- St. Orsola-Malpighi University Hospital,University of Bologna
-
- Steegmann, J. L. (author)
- Hospital Universitario de la Princesa
-
- Turkina, A. (author)
- National Research Center for Hematology
-
- Zaritskey, A. (author)
- Almazov Medical Research Center
-
- Hehlmann, R. (author)
- ELN Foundation,Heidelberg University
-
show less...
-
(creator_code:org_t)
- 2020-03-03
- 2020
- English 19 s.
-
In: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 34:4, s. 966-984
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://www.nature.c...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when molecular milestones are not reached. Greater than 10% BCR-ABL1 at 3 months indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publication and Content Type
- for (subject category)
- ref (subject category)
Find in a library
-
Leukemia
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Hochhaus, A.
-
Baccarani, M.
-
Silver, R. T.
-
Schiffer, C.
-
Apperley, J. F.
-
Cervantes, F.
-
show more...
-
Clark, R. E.
-
Cortes, J. E.
-
Deininger, M. W.
-
Guilhot, F.
-
Hjorth-Hansen, H ...
-
Hughes, T. P.
-
Janssen, J. J.W. ...
-
Kantarjian, H. M ...
-
Kim, D. W.
-
Larson, R. A.
-
Lipton, J. H.
-
Mahon, F. X.
-
Mayer, J.
-
Nicolini, F.
-
Niederwieser, D.
-
Pane, F.
-
Radich, J. P.
-
Rea, D.
-
Richter, J.
-
Rosti, G.
-
Rousselot, P.
-
Saglio, G.
-
Saußele, S.
-
Soverini, S.
-
Steegmann, J. L.
-
Turkina, A.
-
Zaritskey, A.
-
Hehlmann, R.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Leukemia
- By the university
-
Lund University